In patients with unresectable, locally advanced esophageal cancer, the triple combination of radiation, chemotherapy, and ...

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a ...

A new study out of Harvard Medical School is opening the door for cancer patients with a rare but dangerous heart condition ...

Research reveals SLC13A3's role in tumor cell survival and immune therapy resistance, highlighting its potential as a target ...

“Some patients also receive chemotherapy, but the data are mixed on its effectiveness and it’s also very toxic, so we were ...

"We are encouraged to see Efti build upon the historical clinical outcomes from the most widely used immunotherapy-chemo combination today," Chief Executive Marc Voigt said. Early evaluations of an ...

The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell ...

Findings, demonstrated by the phase 2 PERLA trial, were presented at the 2024 Society for Immunotherapy of Cancer (SITC) ...

I have been a cancer doctor for 40 years and have seen our treatments evolve to embrace precision medicine and immunotherapy, which can be less harmful to patients than conventional forms of ...

Encouraging Preclinical Data: Decoy20 has produced efficacy in preclinical studies across a variety of tumor types and in combination with four different classes of existing drugs, demonstrating both ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...